Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise

Detailed Description
-----------------
All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive metformin (rescue medication) added onto their blinded study medication

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Drug: Saxagliptin
* Drug: Saxagliptin
* Drug: Saxagliptin
* Drug: Saxagliptin
* Drug: Placebo
* Drug: metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes Inadequate blood sugar control Exclusion Criteria: Previous treatment for diabetes Current treatment with other medications to lower blood sugar Major heart, liver or kidney problems Women who are pregnant or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 77 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Saxagliptin 2.5 mg QAM (A)<br>PLUS open-label metformin (as needed as rescue medication) | Drug: Saxagliptin<br>* Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)<br>* Other names: BMS-477118;Drug: metformin<br>* Tablets, Oral, 500-2000 mg, as needed (12 months LT)<br>|
| Experimental: Saxagliptin 2.5 mg titrated to 5 mg QAM (B)<br>PLUS open-label metformin (as needed as rescue medication) | Drug: Saxagliptin<br>* Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)<br>* Other names: BMS-477118;Drug: metformin<br>* Tablets, Oral, 500-2000 mg, as needed (12 months LT)<br>|
| Experimental: Saxagliptin 5 mg QAM (C)<br>PLUS open-label metformin (as needed as rescue medication) | Drug: Saxagliptin<br>* Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)<br>* Other names: BMS-477118;Drug: metformin<br>* Tablets, Oral, 500-2000 mg, as needed (12 months LT)<br>|
| Experimental: Saxagliptin 5 mg QPM (D)<br>PLUS open-label metformin (as needed as rescue medication) | Drug: Saxagliptin<br>* Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)<br>* Other names: BMS-477118;Drug: metformin<br>* Tablets, Oral, 500-2000 mg, as needed (12 months LT)<br>|
| Placebo Comparator: Placebo (E)<br>PLUS open-label metformin (as needed as rescue medication) | Drug: Placebo<br>* Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)<br>Drug: metformin<br>* Tablets, Oral, 500-2000 mg, as needed (12 months LT)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Hemoglobin A1 (A1C) at Week 24 | Mean change from baseline in A1C at Week 24, adjusted for baseline value. | Baseline, Week 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM | Mean change from baseline in A1C at Week 24, adjusted for baseline value. | Baseline, Week 24 | 
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | Mean change from baseline in FPG at Week 24, adjusted for baseline value. | Baseline, Week 24 | 
| Percentage of Participants Achieving A1C < 7% at Week 24 | Percentage of participants achieving A1C < 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin versus placebo at Week 24. | Week 24 | 
| Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24 | Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value. | Baseline, Week 24 |